GNCA stock at $0.00 on 19 Feb 2026: market closed, recovery signals weak

GNCA stock closed at $0.00 on 19 Feb 2026 after a one-day decline of -97.44%, making it one of the top losers on the NASDAQ market-close list. Trading volume was 30,268 shares versus a 50-day average near 80,568, reflecting thin liquidity and high directional risk. Investors should note Genocea Biosciences, Inc. (GNCA) is a U.S. biotech with Chapter 11 history and negligible market capitalization, which helps explain extreme price moves and limited analyst coverage.

GNCA stock price action and liquidity

GNCA stock finished the session at $0.00, down -97.44% from the previous close of $0.0039. Volume was 30,268 versus an average of 80,568, which signals low liquidity and wide bid-ask spreads for traders.

Why GNCA fell: company events and market context

Genocea Biosciences, Inc. filed Chapter 11 on July 5, 2022, a material event that has left the equity thinly traded and speculative. The company’s clinical pipeline (GEN-009, GEN-011) and ATLAS platform have limited news flow, and lack of fresh positive catalysts has pressured GNCA stock trading on NASDAQ and OTC venues.

Financials and valuation snapshot for GNCA stock

Key metrics show constrained fundamentals: cash per share $0.54, book value per share $0.39, revenue per share $0.02, and net income per share -0.22. Solvency ratios are mixed with current ratio 2.24 and debt-to-equity 0.41, but market cap reads 0.00 and enterprise value is negative, reflecting distressed equity status.

Meyka AI rates GNCA with a score out of 100 and forecast

Meyka AI rates GNCA with a score out of 100: 62.44 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, forecasts, and analyst signals. Meyka AI’s forecast model projects a one-year median near $0.00 versus the current price (USD 0.0001 raw), implying effectively 0.00% expected upside. Forecasts are model-based projections and not guarantees.

Trading risks, sector view and realistic price targets

GNCA stock faces high volatility, low liquidity, and limited analyst coverage within the Biotechnology sector on the NASDAQ in the United States. Short-term downside case remains $0.00; a speculative recovery target would be $0.01 as a remote upside scenario if restructuring or asset sales produce value. Investors should treat any price target as low-conviction given the company’s history and tiny quoted prices.

Final Thoughts

GNCA stock closed at $0.00 on 19 Feb 2026 after a one-day drop near -97.44% and continued thin trading. The primary drivers remain the company’s Chapter 11 history, limited clinical updates, and effectively zero market capitalization on the NASDAQ and OTC tapes. Meyka AI rates GNCA with a score out of 100 at 62.44 (Grade B, HOLD) based on cross-checks with S&P 500 and sector metrics, financial growth, and analyst signals. Meyka AI’s forecast model projects a one-year median near $0.00 compared to the raw price USD 0.0001, implying no meaningful upside in our baseline model. For investors focused on risk control, GNCA represents a speculative, low-liquidity play where downside remains dominant and any recovery relies on restructuring outcomes or asset realization. We flag a low-probability recovery price target of $0.01 as a high-risk scenario only; forecasts are model-based and are not guarantees. For the latest filings and dividend history see Investing.com GNCA dividends and competitive context from MarketBeat competitor list. Meyka AI is an AI-powered market analysis platform delivering real-time signals and proprietary grades.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.